Back Pain News and Research

Latest Back Pain News and Research

Loyola establishes Mother's Pelvic Wellness Program in Chicago area

Loyola University Health System has established the first multidisciplinary program in the Chicago area to help women recover from pelvic floor disorders related to pregnancy and childbirth.

13 Aug 2013

Intrinsic Therapeutics enrolls 400th patient in randomized clinical trial to evaluate effectiveness of Barricaid prosthesis

Intrinsic Therapeutics today announced the enrollment of the 400th patient in a level 1, prospective, randomized, multi-center clinical trial evaluating the effectiveness of its Barricaid Prosthesis in improving outcomes for lumbar discectomy patients suffering from sciatica.

1 Aug 2013

Severe arthritis pain treatments: an interview with Professor Walsh, University of Nottingham and Professor Wood, UCL

Pain is defined by the sufferer’s experience. Pain may be severe because it is intense, frequent or sustained, and because it is distressing. The severity of pain is not simply due to what is going on in the joint, but is also affected by how the body processes the pain signals, and the context in which it is experienced.

31 Jul 2013

Study finds doctors not following medical guidelines on back pain

Researchers report that physicians are often overly aggressive by prescribing addictive narcotics to patients instead of other recommended drugs and too often using surgery and unneeded imaging tools.

31 Jul 2013

First Edition: July 30, 2013

Today's headlines include a USA Today story reporting that personal health care costs rose in the 12 months ending in May at the slowest rate in the last 50 years -- a finding that makes the White House happy.

30 Jul 2013

Loyola sports medicine physician's advice for parents of high school athletes: Don't let them play football

Prominent sports medicine physician Dr. Pietro Tonino of Loyola University Medical Center has some blunt advice for parents of high school athletes who want to play football this fall: Don't let them do it.

23 Jul 2013

Boston Scientific initiates OPTIMISE trial to study ONS using Precision System for chronic migraine

Boston Scientific Corporation has launched a clinical trial to determine whether occipital nerve stimulation using the Precision System can safely and effectively treat chronic migraine when used in conjunction with anti-migraine medications.

20 Jul 2013

Spinal Restoration: Success criteria not met for primary analysis of Phase III study of Biostat System

Spinal Restoration, Inc. announced today that the success criteria for primary analysis of the Phase III Investigational New Drug study of the Biostat System were not met. The proportions of successful patients that received BIOSTAT BIOLOGX Fibrin Sealant or saline injection were not statistically significantly different when analyzed at the 26-week primary endpoint.

19 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Cell therapies may stop or reverse pain and disability of degenerative disc disease

Cell therapies may stop or reverse the pain and disability of degenerative disc disease and the loss of material between vertebrae, according to Duke University scientists.

17 Jul 2013

UC Riverside study finds that married men are less likely to die of HIV/AIDS

At the height of the AIDS epidemic in the 1980s men who were married were significantly less likely to die of HIV/AIDS than their divorced or otherwise single counterparts, according to a University of California, Riverside analysis of new mortality data for that era.

15 Jul 2013

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.

11 Jul 2013

S.M. Rezaian says that the spine degrades following inadequate treatment

S.M. Rezaian, MD, FRCS, FICS, PhD has treated well over 13,000 patients throughout his illustrious career in orthopedic medicine. He's truly been an innovator in the field, creating the Rezaian Spinal Fixator and applying minimally-invasive laser back surgery both of which allow for more comprehensive and less risky surgical treatments.

6 Jul 2013

Weekly yoga class provides similar lower back pain relief as twice weekly classes for low-income patients

Researchers at Boston University School of Medicine and Boston Medical Center have found that a weekly yoga class provided similar lower back pain relief and reduced the need for pain medication as twice weekly classes in lower income minority patients.

3 Jul 2013

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. announced that following the regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use on April 25, 2013, the European Commission (EC) has granted the marketing authorization for XTANDI™ (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

24 Jun 2013

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, presented results from SETTLE Phase III study with safinamide at the 17th International Congress of Parkinson's disease and Movement Disorders, taking place from June 16 to 20, 2013, at the Sydney Convention and Exhibition Centre, Sydney, Australia.

19 Jun 2013

Spinal infection at contaminated drug injection site detected using contrast-enhanced MRI screening

Magnetic resonance imaging (MRI) at the site of injection of a contaminated lot of a steroid drug to treat symptoms such as back pain resulted in earlier identification of patients with probable or confirmed fungal spinal or paraspinal infection, allowing early initiation of medical and surgical treatment, according to a study in the June 19 issue of JAMA.

19 Jun 2013

European Commission amends marketing authorisation for Celgene's REVLIMID

Celgene International Sàrl was today notified that the European Commission has amended the marketing authorisation for REVLIMID. This decision means that REVLIMID is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

17 Jun 2013

Xgeva receives FDA approval for treating giant cell tumor of the bone

The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone, a rare and usually non-cancerous tumor.

14 Jun 2013

Back Pain News and Research

Latest Back Pain News and Research

Loyola establishes Mother's Pelvic Wellness Program in Chicago area

Intrinsic Therapeutics enrolls 400th patient in randomized clinical trial to evaluate effectiveness of Barricaid prosthesis

Severe arthritis pain treatments: an interview with Professor Walsh, University of Nottingham and Professor Wood, UCL

Study finds doctors not following medical guidelines on back pain

First Edition: July 30, 2013

Loyola sports medicine physician's advice for parents of high school athletes: Don't let them play football

Boston Scientific initiates OPTIMISE trial to study ONS using Precision System for chronic migraine

Spinal Restoration: Success criteria not met for primary analysis of Phase III study of Biostat System

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Cell therapies may stop or reverse pain and disability of degenerative disc disease

UC Riverside study finds that married men are less likely to die of HIV/AIDS

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

S.M. Rezaian says that the spine degrades following inadequate treatment

Weekly yoga class provides similar lower back pain relief as twice weekly classes for low-income patients

Eisai submits BELVIQ NDS with Health Canada

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Spinal infection at contaminated drug injection site detected using contrast-enhanced MRI screening

European Commission amends marketing authorisation for Celgene's REVLIMID

Xgeva receives FDA approval for treating giant cell tumor of the bone

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Back Pain News and Research

Latest Back Pain News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in